Aspirin for lower limb arthroplasty thromboprophylaxis: review of international guidelines
| Autor: | R. Thakral, Claire L. Donohoe, D. M. Niall, M. K. Sayana |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Arthroplasty Replacement Hip Total hip replacement Total knee arthroplasty Lower limb Polysaccharides medicine Humans Intensive care medicine Arthroplasty Replacement Knee Venous Thrombosis Aspirin business.industry Outcome measures Anticoagulants General Medicine Heparin Low-Molecular-Weight Arthroplasty Fondaparinux Lower Extremity Practice Guidelines as Topic Physical therapy business Pulmonary Embolism medicine.drug |
| Zdroj: | Irish journal of medical science. 180(3) |
| ISSN: | 1863-4362 |
| Popis: | Aspirin is one of the pharmacological agents used for thromboprophylaxis. National thromboprophylaxis guidelines, peer-reviewed studies and data from national joint register of England and Wales were analysed for evidence regarding the efficacy of aspirin versus other agents in thromboprophylaxis and the recommendations of guidelines. Two of five guidelines reviewed recommend the use of aspirin for thromboprophylaxis. Aspirin is used as thromboprophylactic agent in approximately 25% of patients undergoing total hip and total knee arthroplasty in year 2006 in England and Wales. There is no difference in mortality in these patients compared to patients on other pharmacological agents. There is conflicting evidence and differences in interpretation of the data from the literature. If specific outcome measures and complications such as symptomatic DVT, PE and bleeding were logged in arthroplasty registers, the resulting data would be useful in individualised decision-making. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink